Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Collegium Pharmaceutical (COLL)

Collegium Pharmaceutical adds Nancy Lurker to board, expanding it to nine directors

Neutral Impact 2 of 5 leadership Written later

Collegium Pharmaceutical's board expanded from eight to nine directors and appointed Nancy Lurker as a director effective February 4, 2025. Ms. Lurker is a former CEO of EyePoint Pharmaceuticals and previously held senior roles at Novartis and other pharmaceutical companies, and the filing states she is independent under Nasdaq rules.

Key points

  • Board expanded from eight to nine directors; Nancy Lurker appointed effective February 4, 2025
  • Lurker receives a $50,000 annual cash retainer, prorated, plus restricted stock units with a $412,500 grant date value
  • Her restricted stock units vest on the first anniversary of the grant, subject to continued service; her term runs to the 2025 Annual Meeting

The filing

CompanyCollegium Pharmaceutical (COLL)
Form8-K, current report
Filed with the SECFeb 5, 2025, 8:05 AM ET
Accession number0001104659-25-009384

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:07 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 05, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.